Form 4 for RGEN REPLIGEN CORP
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-23 · accession 0000950170-24-020513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-23 | RGEN | Bylund James | COO | S - Sale+OE | $198.08 | -4,373 | 14.1K | -24% | -$866.2K |
| D | 2024-02-26 | 2024-02-23 | RGEN | Bylund James | COO | M - OptEx | $94.33 | +940 | 18.5K | +5% | +$88.7K |
| D | 2024-02-26 | 2024-02-23 | RGEN | Bylund James | COO | M - OptEx | $0.00 | +940 | 4,000 | +31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | S | D | 4,373 | $198.08 | 14,135 | D | — | — | (F1) $198.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.73 to $198.46 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2024-02-23 | M | A | 940 | $94.33 | 18,508 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-23 | M | A | 940 | $0.00 | 4,000 | D | $94.33 · — to 2030-04-01 | 940 Common Stock | (F2) 2,000 shares vest and become exercisable on both 4/1/2024 and 4/1/2025. |